Ocugen Inc (OCGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ocugen Inc (OCGN) has a cash flow conversion efficiency ratio of -3.754x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.79 Million) by net assets ($5.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see OCGN market cap for the company's overall valuation and market capitalisation.
Ocugen Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Ocugen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ocugen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ocugen Inc ranked by their cash flow conversion efficiency. Explore Ocugen Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Revenio Group Corporation
HE:REG1V
|
-0.029x |
|
Santana Minerals Ltd
AU:SMI
|
-0.008x |
|
Stillfront Group AB (publ)
ST:SF
|
0.040x |
|
KG Mobility Corp.
KO:003620
|
0.049x |
|
Hunan Hengguang Technology Co.Ltd.
SHE:301118
|
0.049x |
|
Joy Kie Corporation Limited.
SHE:300994
|
0.052x |
|
Parpro Corp
TW:4916
|
0.001x |
|
CPH Chemie und Papier Holding
SW:CPHN
|
0.100x |
Annual Cash Flow Conversion Efficiency for Ocugen Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Ocugen Inc from 2012 to 2025. View OCGN stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-12.17 Million | $-56.96 Million | 4.682x | +429.23% |
| 2024-12-31 | $29.63 Million | $-42.14 Million | -1.422x | +7.03% |
| 2023-12-31 | $40.56 Million | $-62.05 Million | -1.530x | -88.38% |
| 2022-12-31 | $73.98 Million | $-60.08 Million | -0.812x | -62.31% |
| 2021-12-31 | $95.82 Million | $-47.94 Million | -0.500x | +26.70% |
| 2020-12-31 | $21.55 Million | $-14.71 Million | -0.683x | +55.48% |
| 2019-12-31 | $11.02 Million | $-16.89 Million | -1.533x | -104.45% |
| 2018-12-31 | $-458.00K | $-15.78 Million | 34.448x | +1586.17% |
| 2017-12-31 | $-11.27 Million | $-23.02 Million | 2.043x | +207.70% |
| 2016-12-31 | $13.57 Million | $-25.74 Million | -1.897x | -78.10% |
| 2015-12-31 | $28.20 Million | $-30.03 Million | -1.065x | -213.69% |
| 2014-12-31 | $54.21 Million | $-18.41 Million | -0.340x | -267.87% |
| 2013-12-31 | $-75.55 Million | $-15.28 Million | 0.202x | -67.41% |
| 2012-12-31 | $-19.71 Million | $-12.23 Million | 0.621x | -- |
About Ocugen Inc
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase… Read more